Sharon Benzeno's most recent trade in Adaptive Biotechnologies Corp was a trade of 12,604 Common Stock done at an average price of $16.8 . Disclosure was reported to the exchange on Dec. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 16.85 per share. | 04 Dec 2025 | 12,604 | 296,791 (0%) | 0% | 16.8 | 212,377 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 04 Dec 2025 | 4,290 | 301,081 (0%) | 0% | 12.1 | 52,081 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 4,290 | 12,871 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 4,157 | 112,247 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 4,157 | 62,360 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.99 per share. | 04 Dec 2025 | 4,157 | 309,395 (0%) | 0% | 4.0 | 16,586 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 04 Dec 2025 | 4,157 | 305,238 (0%) | 0% | 8.5 | 35,168 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 16.91 per share. | 20 Nov 2025 | 308,477 | 296,791 (0%) | 0% | 16.9 | 5,216,346 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 16.54 per share. | 20 Nov 2025 | 297,925 | 296,791 (0%) | 0% | 16.5 | 4,927,680 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 20 Nov 2025 | 133,032 | 525,755 (0%) | 0% | 8.5 | 1,125,451 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 133,032 | 66,517 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 20 Nov 2025 | 119,809 | 522,123 (0%) | 0% | 12.1 | 1,454,481 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 119,809 | 17,161 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 83,145 | 116,404 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.99 per share. | 20 Nov 2025 | 83,145 | 605,268 (0%) | 0% | 4.0 | 331,749 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 20 Nov 2025 | 68,961 | 594,716 (0%) | 0% | 12.1 | 837,187 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 68,961 | 136,970 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 20 Nov 2025 | 49,480 | 367,939 (0%) | 0% | 6.6 | 324,094 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 49,480 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 20 Nov 2025 | 34,375 | 402,314 (0%) | 0% | 7.3 | 249,906 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 34,375 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 20 Nov 2025 | 20,834 | 318,459 (0%) | 0% | 6.6 | 136,463 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 20,834 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.27 per share. | 20 Nov 2025 | 834 | 297,625 (0%) | 0% | 6.3 | 5,229 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2025 | 834 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 165,027 | 165,027 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 109,973 | 437,388 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 41,600 | 395,788 (0%) | 0% | 7.0 | 290,368 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 3,065 | 392,723 (0%) | 0% | 7.0 | 21,424 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 356,805 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 18,644 | 327,415 (0%) | 0% | 3.4 | 64,135 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 10,746 | 346,059 (0%) | 0% | 3.4 | 36,859 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 132,979 | 235,575 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 11,749 | 223,826 (0%) | 0% | 8.6 | 100,689 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 205,931 | 205,931 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 82,372 | 105,266 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 2,670 | 102,596 (0%) | 0% | 12.0 | 32,067 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 15 Mar 2021 | 1,354 | 24,248 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 1,354 | 47,396 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.85 per share. | 15 Mar 2021 | 1,014 | 22,894 (0%) | 0% | 41.9 | 42,436 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.22 per share. | 15 Mar 2021 | 340 | 23,908 (0%) | 0% | 41.2 | 14,015 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 57,234 | 57,234 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 57.57 per share. | 01 Mar 2021 | 6,210 | 561 (0%) | 0% | 57.6 | 357,510 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 2,604 | 2,604 (0%) | 0% | 6.5 | 17,056 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,604 | 49,480 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,604 | 20,834 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Mar 2021 | 1,563 | 6,771 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 1,563 | 34,375 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 58.17 per share. | 01 Mar 2021 | 561 | 0 (0%) | 0% | 58.2 | 32,633 | Common Stock |